Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis.

@article{Chierakul2006PharmacokineticAP,
  title={Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis.},
  author={Wirongrong Chierakul and Jinda Wangboonskul and Thida Singtoroj and Wirichada Pongtavornpinyo and Jennifer M. Short and Bina Maharjan and Vanaporn Wuthiekanun and David A B Dance and Prapit Teparrukkul and Niklas Lindeg{\aa}rdh and Sharon J Peacock and Nicholas P J Day and Wipada Chaowagul and Nicholas J White},
  journal={The Journal of antimicrobial chemotherapy},
  year={2006},
  volume={58 6},
  pages={1215-20}
}
OBJECTIVES We conducted a prospective pharmacokinetic study of oral co-amoxiclav in patients with melioidosis to determine the optimal dosage and dosing interval in this potentially fatal infection. PATIENTS AND METHODS Serial plasma concentrations were measured after administration of two 1 g tablets of Augmentin (1750 mg of amoxicillin and 250 mg of clavulanate) to 14 adult patients with melioidosis. Monte Carlo simulation was used to predict the concentration of each drug following… CONTINUE READING

Similar Papers

Loading similar papers…